Evidence for genetic heterogeneity in malignant hyperthermia susceptibility.

doi:10.1016/0888-7543(91)90061-i

Back to search

Article

Evidence for genetic heterogeneity in malignant hyperthermia susceptibility.

Genomics - 1 Nov 1991

Levitt R C, Nouri N, Jedlicka A E, McKusick V A, Marks A R, Shutack J G, Fletcher J E, Rosenberg H, Meyers D A

Abstract excerpt

Malignant hyperthermia susceptibility (MHS) is a clinically heterogeneous pharmacogenetic disorder characterized by accelerated metabolism, hyperthermia, and frequently muscle rigidity. MHS is elicited by all commonly used potent inhalation anesthetics and depolarizing neuromuscular blockers and...

Topics

Chromosomes, Human, Pair 19
Disease Susceptibility
Female
Genetic Linkage
Genetic Markers
Genetic Variation
Haplotypes
Humans
Male
Malignant Hyperthermia
Pedigree
Polymorphism, Genetic

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.